Orexo AB (publ) (ORXOF)

Market Cap	77.33M
Revenue (ttm)	59.47M
Net Income (ttm)	-20.92M
Shares Out	n/a
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	55
Open	2.020
Previous Close	n/a
Day's Range	2.020 - 2.020
52-Week Range	1.080 - 2.020
Beta	0.51
RSI	100.00
Earnings Date	Jul 16, 2025

About Orexo AB

Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 110
• Stock Exchange: OTCMKTS
• Ticker Symbol: ORXOF

Financial Performance

In 2024, Orexo AB's revenue was 590.00 million, a decrease of -7.64% compared to the previous year's 638.80 million. Losses were -203.00 million, 58.2% more than in 2023.

Financial numbers in SEK